44 2033180199
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Journal of Phlebology and Lymphology

Sign up for email alert when new content gets added: Sign up

Alessandro Mandurino-Mirizzi1,2*, Marcello Spolverini1,2, Andrea Attanasio1,2 and Gabriele Crimi1
 
1 Division of Cardiology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Email: [email protected]
2 University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
 
*Correspondence: Alessandro Mandurino-Mirizzi, Cardiology Department, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Tel: +39 0382 503158, Email: [email protected]

Received: 18-Feb-2020 Accepted Date: Mar 05, 2020; Published: 12-Mar-2020

Citation: Mirizzi AM, Spolverini M, Attanasio A, Crimi G. Management of noreflow Still an unsolved problem? J Phlebol Lymphol 2020;13(1):1-7.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact [email protected]

Abstract

No-reflow represents an important limitation of percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Importantly, no-reflow is associated with an increased risk of major adverse cardiac events. In this review, we discuss the pharmacological and nonpharmacological interventions proposed for the prevention and treatment of no-reflow, highlighting the new updates and evidences on efficacy of these approaches.

 
Google Scholar citation report
Citations : 132

Journal of Phlebology and Lymphology received 132 citations as per Google Scholar report

Top